Background: Toxoplasmosis is a disease caused by Toxoplasma gondii, which can infect nearly all mammalian and avian species. Approximately 25% of the global human population is thought to be infected. Interest in toxoplasmosis has surged since it was discovered that with the onset of acquired immune deficiency syndrome, acute toxoplasmosis could induce cranial calcification. The ensuing encephalitis can be fatal. The African human immunodeficiency virus (HIV) epidemic, increasing levels of other immunosuppressive infections (such as tuberculosis), poor sanitation practices and lack of monitoring of at-risk populations point to a predicament that may be underrated.
Introduction
Over the years, there have been scattered, sporadic (and usually small) studies on Toxoplasma gondii seroprevalence in the African continent, and this is unfortunate. The current human immunodeficiency virus (HIV) epidemic on the continent, increasing levels of other immunosuppressive infections (such as tuberculosis), poor sanitation and hygiene practices, inadequate veterinary services, and high levels of poverty, coupled with lack of proactive monitoring of at-risk populations and reporting of these investigations, is part of the challenge. The absence of public health schemes to manage the spread of this pathogen places African populations at risk of ongoing and possibly increasing incidence and prevalence, as well as a corresponding increase in mortality and morbidity due to toxoplasmosis. This may be the case in particular for toxoplasma encephalitis, which is currently a leading cause of mortality and morbidity in HIV patients who have progressed to full blown acquired immune deficiency syndrome, (AIDS) who and are not on highly active antiretroviral therapy in Africa. 1 There have been few studies on seroprevalence rates of T. gondii in animal species on the African continent. Given the large numbers of domestic and wild animals in Africa, as well as the lack of sophisticated animal husbandry, there is a high likelihood of transmission and hence mobility of the pathogen from animal hosts to human hosts, together with an increased risk of morbidity and mortality.
Method
A literature search of the National Centre for Biotechnology Information, Pubmed, Google Scholar and ToxoDB databases was performed, with the keywords "Toxoplasma gondii seroprevalence studies in Africa". This was then followed by another search using the keywords "toxoplasmosis in Africa". A further search was carried out on the references of the selected publications, as well S Afr Fam Pract 2014 as on infectious diseases congress reports and abstract compilations. Publications were selected using the year end 2012 as a cut-off.
Confidence intervals pertaining to seroprevalence rates for each reported study were derived from the corresponding publication, where available.
Results
Monitoring and reporting on T. gondii seroprevalence in Africa has been less than adequate since the first report was published in 1971. The seroprevalence surveys that were conducted did not focus on comparable cohorts over time. Therefore, caution needs to be exercised when interpreting the data. The data presented in Tables I, II and III (and Table IV for animals), classify the investigations according to the locations in which they were conducted, the sample size of the study, the year in which the study was conducted in chronological order, the level of seroprevalence as a percentage, as well as the type of population investigated.
Discussion

Toxoplasmosis in immunocompetent individuals
Studies on T. gondii in asymptomatic individuals in Africa are limited in number, and none of the countries follow a systematic planned pattern of reporting (Table  I) . Seroprevalence rates range from 6.4-74.5%, with a median of 37%. The first reported study was from South Africa, by Mason, Jacobs and Fripp 2 in 1974, whereby a seroprevalence of 20% was found in a cohort comprising black, white, Indian and coloured immunocompetent individuals. Since then, other studies, the most recent being Kistiah et al, 18 have reported a 6.4% seroprevalence in a generalised cohort, but it was biased towards pregnant women. Swai and Schoonman 16 reported seroprevalence of 45.7% in a Tanzanian cohort predominantly comprising immunocompetent individuals who were exposed to livestock via their occupation (abattoir workers, livestock keepers and animal health workers). Zumla et al 6 reported seroprevalence of 27% in Uganda, while Griffin and Williams 
Women of reproductive age and pregnant women
A number of studies have been conducted on the risk group of women of reproductive age and pregnant women. Most of the studies were carried out in the west and north of Africa. The south and the east are under-represented in studies (Table II) 
Human immunodeficiency virus-and acquired immune deficiency syndrome-related toxoplasmosis
With the advent of the HIV-AIDS era, the significance of toxoplasmosis was realised, resulting in an increase in the number of seroprevalence investigations, particularly in HIV-positive, compared to HIV-negative, populations (Table III) . Seroprevalence rates range from 4-80%, with a median of 36.35%. The highest seroprevalence of T. gondii 41 with 80% seroprevalence in 170 patients tested. The average seroprevalence figure was 52% in west Africa, ranging from 62.5% in Burkina Faso, to 21% in Ivory Coast, by Ledru et al 39 and Lucas et al, 38 respectively. The lowest rate on the continent, 4%, was recorded in Zambia by Zumla et al. 6 Lindström et al 1 and Brindle, Holliman, Gilks and Waiyaki 37 reported seroprevalence rates of 54% in Uganda and Kenya, respectively. Only one study was reported from the north of Africa. It was by Addebbous et al 48 in Morocco, where a seroprevalence rate of 62.5% was provided. Seroprevalence studies in the southern part of Africa have mostly derived from South Africa. Sonnenberg, Silber and Jentsch 42 reported the highest seroprevalence rate of 24.6% in KwaZulu-Natal province. The lowest rate of 8% was reported in Gauteng province by Hari, Modi, Mochan and Modi. 44 Seroprevalence rates follow an increasing trend in northern Africa from 11.7% in 2010 to 62.1% in 2012. There was also an increasing trend in southern Africa from 4% in 1991 to 9.8% in 2011, in western Africa of 21% in 1993 to 38.2% in 2013, and in eastern Africa from 34% in 1991 to 54% in 2006.
Toxoplasmosis in animal species
Most of the studies reported to date have been carried out in the southern part of Africa (Table IV) 
Conclusion
Overall, seroprevalence rates on the continent are very high in both human and animal populations. The data suggest a geographical trend, with decreasing seroprevalence from the northern to the southern, and from the western to the eastern, regions of the continent. Most seroprevalence studies on humans were reported between 1981 and 2000. The majority of the serosurveys were carried out on immunocompetent individuals, followed by women of reproductive age, and then on HIV/AID patients. Only a limited number of these studies took into consideration risk factors that are most important for infection with the pathogen. Thus, very few surveys have been performed with regard to animals in order to understand zoonotic risk. If risk factors from studies in other parts of the world are taken into account, it is possible to infer that large numbers of people on the African continent, such as pregnant women and HIV-positive individuals, are at risk of a primary infection or reactivation of a chronic infection. Seroprevalence rates generally demonstrated decreasing trends over time in northern, southern and eastern Africa in all the groups studied. A noteworthy exception was western Africa, where seroprevalence rates showed an increasing trend over time in all the groups, and in HIV-AIDS patient cohorts where prevalence rates showed an increasing trend over time in all the regions. These data suggest that overall seroprevalence rates follow an increasing gradient from relatively low prevalence in the southern part of the continent, to moderate to high in the west and east, and highest in the northern part of Africa. These findings must be taken seriously, and further structured investigations carried out to ascertain the causative factors and action required to mitigate their effects.
This information is important because even if only 5% of individuals are infected and present with clinical manifestations, the implications for the burden of disease in Africa, with a population approaching one billion, are staggering. Given that toxoplasmosis is associated with clinical manifestation in HIV-positive individuals, and given that reactivation of a latent infection can be life-threatening 58 owing to a number of factors, including increased immunosuppression and encephalitis, 49 it is possible that this disease may be a neglected driver for clinical diseases such as tuberculosis, or other chronic or infectious illnesses that might otherwise not manifest themselves. In this case, the burden of disease and disability-adjusted life year cost to Africa from toxoplasmosis is considerable and deserves attention.
